WO2023207991A1 - Composé de quinazoline fusionné et son utilisation - Google Patents

Composé de quinazoline fusionné et son utilisation Download PDF

Info

Publication number
WO2023207991A1
WO2023207991A1 PCT/CN2023/090625 CN2023090625W WO2023207991A1 WO 2023207991 A1 WO2023207991 A1 WO 2023207991A1 CN 2023090625 W CN2023090625 W CN 2023090625W WO 2023207991 A1 WO2023207991 A1 WO 2023207991A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
ring
pharmaceutically acceptable
acceptable salt
membered
Prior art date
Application number
PCT/CN2023/090625
Other languages
English (en)
Chinese (zh)
Inventor
陈曙辉
李鹏
王正
贺海鹰
Original Assignee
南京明德新药研发有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南京明德新药研发有限公司 filed Critical 南京明德新药研发有限公司
Publication of WO2023207991A1 publication Critical patent/WO2023207991A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/153—Ortho-condensed systems the condensed system containing two rings with oxygen as ring hetero atom and one ring with nitrogen as ring hetero atom

Definitions

  • the present invention relates to fused quinazoline compounds and their applications, specifically to the compounds represented by formula (I) and their pharmaceutically acceptable salts.
  • R 1 is selected from -CH 3 ;
  • the term "pharmaceutically acceptable” refers to those compounds, materials, compositions and/or dosage forms which, within the scope of sound medical judgment, are suitable for use in contact with human and animal tissue. , without undue toxicity, irritation, allergic reactions, or other problems or complications, commensurate with a reasonable benefit/risk ratio.
  • salts refers to salts of compounds of the present invention prepared from compounds having specific substituents found in the present invention and relatively non-toxic acids or bases.
  • base addition salts can be obtained by contacting such compounds with a sufficient amount of base in pure solution or in a suitable inert solvent.
  • Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amine or magnesium salts or similar salts.
  • acid addition salts can be obtained by contacting such compounds with a sufficient amount of acid in neat solution or in a suitable inert solvent.
  • a diastereomeric salt is formed with a suitable optically active acid or base, and then the salt is formed by conventional methods known in the art. Diastereomeric resolution is performed and the pure enantiomers are recovered. Furthermore, the separation of enantiomers and diastereomers is usually accomplished by the use of chromatography using chiral stationary phases, optionally combined with chemical derivatization methods (e.g., generation of amino groups from amines). formate).
  • C n-n+m or C n -C n+m includes any specific case of n to n+m carbons, for example, C 1-12 includes C 1 , C 2 , C 3 , C 4 , C5 , C6 , C7 , C8 , C9 , C10 , C11 , and C12 , also include any range from n to n+m, for example, C1-12 includes C1-3 , C 1-6 , C 1-9 , C 3-6 , C 3-9 , C 3-12 , C 6-9 , C 6-12 , and C 9-12 , etc.; similarly, n yuan to n The +m member indicates that the number of atoms in the ring is n to n+m.
  • C 1-4 alkyl is used to mean a straight or branched chain saturated hydrocarbon group consisting of 1 to 4 carbon atoms.
  • the C 1-4 alkyl group includes C 1-2 , C 1-3 and C 2-3 alkyl groups, etc.; it can be monovalent (such as methyl), divalent (such as methylene) or multivalent ( Such as methine).
  • Examples of C 1-4 alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n-propyl and isopropyl), butyl (including n-butyl, isobutyl , s-butyl and t-butyl), etc.
  • C 2-6 alkenyl is used to mean a straight or branched hydrocarbon group consisting of 2 to 6 carbon atoms containing at least one carbon-carbon double bond. Can be located anywhere on the group.
  • the C 2-6 alkenyl group includes C 2-4 , C 2-3 , C 4 , C 3 and C 2 alkenyl groups, etc.; it can be monovalent, divalent or multivalent.
  • Examples of C 2-6 alkenyl groups include, but are not limited to, vinyl, propenyl, butenyl, pentenyl, hexenyl, butadienyl, piperylene, hexadienyl, and the like.
  • G 1-4 alkoxy means those alkyl groups containing 1 to 4 carbon atoms that are attached to the remainder of the molecule through an oxygen atom.
  • the C 1-4 alkoxy group includes C 1-3 , C 1-2 , C 2-4 , C 4 and C 3 alkoxy groups, etc.
  • Examples of C 1-4 alkoxy include, but are not limited to, methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), butoxy (including n-butoxy, isobutoxy Oxygen, s-butoxy and t-butoxy), etc.
  • C 6-12 aryl groups include C 6-10 , C 6-9 , C 6-8 , C 12 , C 10 and C 6 aryl groups, etc.
  • Examples of C 6-12 aryl groups include, but are not limited to, phenyl, naphthyl (including 1-naphthyl, 2-naphthyl, etc.).
  • the 5-12-membered heteroaryl group includes 5-10-membered, 5-8-membered, 5-7-membered, 5-6-membered, 5-membered and 6-membered heteroaryl groups, etc.
  • Examples of the 5-12 membered heteroaryl include, but are not limited to, pyrrolyl (including N-pyrrolyl, 2-pyrrolyl and 3-pyrrolyl, etc.), pyrazolyl (including 2-pyrazolyl and 3-pyrrolyl).
  • the structure of the compound of the present invention can be confirmed by conventional methods well known to those skilled in the art. If the present invention involves the absolute configuration of the compound, the absolute configuration can be confirmed by conventional technical means in the art.
  • single crystal X-ray diffraction uses a Bruker D8 venture diffractometer to collect diffraction intensity data on the cultured single crystal.
  • the light source is CuK ⁇ radiation.
  • the scanning method is: After scanning and collecting relevant data, the direct method (Shelxs97) is further used to analyze the crystal structure, and the absolute configuration can be confirmed.
  • compound A-3 (677 mg, 1.82 mmol) was dissolved in toluene (10 mL), and methylmagnesium bromide solution (3M, 2.43 mL) was added at 0°C. The reaction solution was stirred and reacted at 25°C for 2 hours. Add saturated ammonium chloride solution (10 mL) to quench, and extract with ethyl acetate (10 mL ⁇ 2). The organic phase was washed with saturated brine (10 mL ⁇ 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure.
  • IC 50 can be obtained by curve fitting with four parameters (log(inhibitor) vs. response in GraphPad Prism --Variable slope mode derived).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne un composé de quinazoline fusionné et son utilisation. Spécifiquement, la présente invention concerne un composé tel que représenté par la formule (IV) et un sel pharmaceutiquement acceptable de celui-ci.
PCT/CN2023/090625 2022-04-29 2023-04-25 Composé de quinazoline fusionné et son utilisation WO2023207991A1 (fr)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
CN202210476471 2022-04-29
CN202210476471.4 2022-04-29
CN202210616048.X 2022-05-31
CN202210616048 2022-05-31
CN202210693539 2022-06-17
CN202210693539.4 2022-06-17
CN202210843991 2022-07-18
CN202210843991.4 2022-07-18
CN202210936894 2022-08-05
CN202210936894.X 2022-08-05
CN202211074025.7 2022-09-02
CN202211074025 2022-09-02

Publications (1)

Publication Number Publication Date
WO2023207991A1 true WO2023207991A1 (fr) 2023-11-02

Family

ID=88517751

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/090625 WO2023207991A1 (fr) 2022-04-29 2023-04-25 Composé de quinazoline fusionné et son utilisation

Country Status (1)

Country Link
WO (1) WO2023207991A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1534026A (zh) * 2002-03-28 2004-10-06 �Ϳ���ҽҩ��˾ 新型作为酪氨酸激酶抑制剂的稠合的喹唑啉衍生物
WO2021203768A1 (fr) * 2020-04-08 2021-10-14 江苏恒瑞医药股份有限公司 Dérivé pyrimido dicyclo, son procédé de préparation et son utilisation en médecine
WO2022061348A1 (fr) * 2020-09-16 2022-03-24 Biotheryx, Inc. Agents de dégradation de protéine sos1, compositions pharmaceutiques de ceux-ci, et leurs applications thérapeutiques
WO2022199635A1 (fr) * 2021-03-25 2022-09-29 南京明德新药研发有限公司 Dérivés de benzylaminoquinazoline

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1534026A (zh) * 2002-03-28 2004-10-06 �Ϳ���ҽҩ��˾ 新型作为酪氨酸激酶抑制剂的稠合的喹唑啉衍生物
WO2021203768A1 (fr) * 2020-04-08 2021-10-14 江苏恒瑞医药股份有限公司 Dérivé pyrimido dicyclo, son procédé de préparation et son utilisation en médecine
WO2022061348A1 (fr) * 2020-09-16 2022-03-24 Biotheryx, Inc. Agents de dégradation de protéine sos1, compositions pharmaceutiques de ceux-ci, et leurs applications thérapeutiques
WO2022199635A1 (fr) * 2021-03-25 2022-09-29 南京明德新药研发有限公司 Dérivés de benzylaminoquinazoline

Similar Documents

Publication Publication Date Title
CN115335372B (zh) 八氢吡嗪并二氮杂萘啶二酮类化生物
CN112105618B (zh) 作为选择性HER2抑制剂的吡咯并[2,1-f][1,2,4]三嗪类衍生物及其应用
CN116888128A (zh) 嘧啶并芳香环类化合物
WO2019157879A1 (fr) Composé hétérocyclique agissant en tant qu'inhibiteur de trk
WO2020259573A1 (fr) Dérivé hétérocyclique à sept chaînons agissant en tant qu'inhibiteur de protéine mutante kras g12c
WO2022199670A1 (fr) Dérivés cycliques hétéroaryle substitués par un groupe 6-carbamate
CN112771045B (zh) 喹啉并吡咯烷-2-酮类衍生物及其应用
KR20210123360A (ko) c-Met억제제로서 피리미디닐기를 포함하는 삼환식 화합물
CN114786778A (zh) 治疗性化合物
WO2023280317A1 (fr) Composé benzylamino tricyclique et son utilisation
CN113227051A (zh) 用于视网膜疾病的化合物
WO2023160572A1 (fr) Dérivé de pyrazole, composition pharmaceutique et utilisation
KR20230154953A (ko) 푸란 축합 고리로 치환된 글루타르이미드계 화합물
CN114450289B (zh) 作为选择性btk激酶抑制剂的吡唑并吡啶类化合物
WO2020156568A1 (fr) Composé fluorovinylbenzamide utile en tant qu'immunomodulateur pd-l1
CN114096245B (zh) 作为ccr2/ccr5拮抗剂的杂环烷基类化合物
AU2018364218A1 (en) SMAC mimetics used as IAP inhibitors and use thereof
WO2024051727A1 (fr) Dérivé de pyrazole, composition pharmaceutique et utilisation
CN112574278A (zh) 作为蛋白降解剂杂环类化合物及其制备方法和医药应用
WO2023207991A1 (fr) Composé de quinazoline fusionné et son utilisation
CN111315750B (zh) 作为mTORC1/2双激酶抑制剂的吡啶并嘧啶类化合物
EP3978492A1 (fr) Composé bicyclique en tant qu'inhibiteur de la kinase rip-1 et son application
JP7296017B2 (ja) ベンゾスルタムを含む化合物
WO2023016527A1 (fr) Classe de composés spiro de benzoxazine et procédé de préparation correspondant
WO2022057836A1 (fr) Dérivé cyclique de benzourée, son procédé de préparation et son utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23795423

Country of ref document: EP

Kind code of ref document: A1